Intravenous vancomycin/linezolid for intracranial infection after neurosurgery: a cerebrospinal fluid PK/PD study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044495

Enrollment

Unknown

Registered

2021-03-23

Start date

2021-05-01

Completion date

Unknown

Last updated

2021-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intracranial infection

Interventions

Vancomycin group for intracranial infection:vancomycin

linezolid group for intracranial infection:linezolid

Vancomycin group was infected with other sites:vancomycin

linezolid group was infected with other sites :linezolid

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Intracranial infection/infection of other parts after neurosurgery; 2. Aged 18-70 years; 3. The pathogen was determined to be G+ coccus by specimen culture or DNA detection; 4. Informed consent.

Exclusion criteria

Exclusion criteria: 1. Adverse reactions to corresponding antimicrobial agents; 2. Cerebrospinal fluid cannot be obtained; 3. Patients with severe heart, kidney and other basic diseases; 4. Accepted corresponding drug therapy within one month; 5. Hormone preparation should be used during antimicrobial treatment.

Design outcomes

Primary

Measure	Time frame
Cerebrospinal fluid drug concentration;blood concentration;The concentration-time curve;	—

Secondary

Measure	Time frame
Serum procalcitonin;CSF procalcitonin;CSF-LDH;	—

Countries

China

Contacts

Public ContactMing-Chao Fan

The Affiliated Hospital of Qingdao University

fanmcchina@126.com+86 17853292728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026